Professor of Neurosurgery and Neurology, University of California, San Francisco, Department of Neurological Surgery
Dr. Bankiewicz received his MD degree from Jagiellonian University in Crakow and his PhD degree from the Institute of Neurology and Psychiatry in Warsaw, Poland. After his residency and an appointment as Assistant Professor with the Post-graduate Medical Center in Warsaw, he received a Fogarty Fellowship and became a Visiting Fellow and then Visiting Associate Scientist with the Surgical Neurology Branch of the NINDS at the NIH in Bethesda, Maryland. There, he became Chief of the Central Nervous System (CNS) Implantation Unit in 1991.
Shortly afterward, he came to California to serve as Chief of Preclinical Studies with the Somatix Therapy Corporation in Alameda; the Director of the Division of CNS Implantation and Regeneration with The Parkinson's Institute in Sunnyvale, and from 1994-1998, a Visiting Scientist with the Laboratory for Functional Imaging of the Lawrence Berkeley National Laboratory. From 1997-2001 he returned to the NIH as Acting Chief of the Molecular Therapeutics Section of NINDS. He has been Professor of Neurological Surgery and a Principal Investigator with the Movement Disorders Research Program and the Brain Tumor Research Center at the University of California San Francisco (UCSF) since 1998.
Dr. Bankiewicz is a inventor of 8 patents, and has published more than 100 peer-reviewed research articles. Dr. Bankiewicz has considerable experience in supervising multi-investigator translational programs. He is a Principal Investigator on several multi-center, multi-investigator grants. He has supervised a total of 25 post-doctoral fellows, and manages a core research group of 20 individuals including technicians, post-doctoral fellows, and a senior scientist. He is currently Professor (In Residence) in the Neurosurgery and Neurology Departments at UCSF (San Francisco, CA).
Throughout his career, he has maintained a strong focus on the development of practical approaches to gene and cell replacement therapies, and has displayed a remarkable ability to synthesize several individual technologies into powerful new approaches to the treatment of such serious disease as brain cancer and neurodegenerative disorders of the brain, including Parkinson's disease. Dr. Bankiewicz was instrumental at every stage of the Phase-1 clinical trial for AAV-hAADC gene therapy, now underway at UCSF, in resolving technical and scientific issues with respect to filing an IND application with the FDA, and also in recruiting a clinical team to undertake the clinical trial.